
J.P. Morgan upgrades gene therapy maker bluebird bio BLUE.O to "neutral" from "underweight" rating, citing co's announcement that it would be taken private
Brokerage expects co's privatization to take place within 1H25
BLUE says it will be taken private by Carlyle CG.O and SK Capital Partners
1 of 8 brokerages rate BLUE stock "buy", 7 "hold"; their median PT is $10 - LSEG data
As of last close, stock down ~51.1% YTD